Literature DB >> 33077197

A postdischarge venous thromboembolism risk calculator for inflammatory bowel disease surgery.

Cary Jo R Schlick1, Tarik K Yuce1, Anthony D Yang1, Michael F McGee1, David J Bentrem2, Karl Y Bilimoria3, Ryan P Merkow4.   

Abstract

BACKGROUND: Guidelines recommend extended chemoprophylaxis for venous thromboembolism in high-risk patients having operations for inflammatory bowel disease. Quantifying patients' risk of venous thromboembolism, however, remains challenging. We sought (1) to identify factors associated with postdischarge venous thromboembolism in patients undergoing colorectal resection for inflammatory bowel disease and (2) to develop a postdischarge venous thromboembolism risk calculator to guide prescribing of extended chemoprophylaxis.
METHODS: Patients who underwent an operation for inflammatory bowel disease from 2012 to 2018 were identified from the American College of Surgeons National Surgical Quality Improvement Program for colectomy and proctectomy procedure targeted modules. Postdischarge venous thromboembolism included pulmonary embolism or deep vein thrombosis diagnosed after discharge from the index hospitalization. Multivariable logistic regression estimated the association of patient/operative factors with postdischarge venous thromboembolism. A postdischarge venous thromboembolism risk calculator was subsequently constructed.
RESULTS: Of 18,990 patients, 199 (1.1%) developed a postdischarge venous thromboembolism within the first 30 postoperative days. Preoperative factors associated with postdischarge venous thromboembolism included body mass index (1.9% with body mass index ≥35 vs 0.8% with body mass index 18.5-24.9; odds ratio 2.34 [95% confidence interval 1.49-3.67]), steroid use (1.3% vs 0.7%; odds ratio 1.91 [95% confidence interval 1.37-2.66]), and ulcerative colitis (1.5% vs 0.8% with Crohn's disease; odds ratio 1.76 [95% confidence interval 1.32-2.34]). Minimally invasive surgery was associated with postdischarge venous thromboembolism (1.2% vs 0.9% with open; odds ratio 1.42 [95% confidence interval 1.05-1.92]), as was anastomotic leak (2.8% vs 1.0%; odds ratio 2.24 [95% confidence interval 1.31-3.83]) and ileus (2.1% vs 0.9%; odds ratio 2.60 [95% confidence interval 1.91-3.54]). The predicted probability of postdischarge venous thromboembolism ranged from 0.2% to 14.3% based on individual risk factors.
CONCLUSION: Preoperative, intraoperative, and postoperative factors are associated with postdischarge venous thromboembolism after an operation for inflammatory bowel disease. A postdischarge venous thromboembolism risk calculator was developed which can be used to tailor extended venous thromboembolism chemoprophylaxis by individual risk.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33077197      PMCID: PMC7856037          DOI: 10.1016/j.surg.2020.09.006

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  67 in total

1.  Design and statistical methodology of the National Surgical Quality Improvement Program: why is it what it is?

Authors:  William G Henderson; Jennifer Daley
Journal:  Am J Surg       Date:  2009-11       Impact factor: 2.565

2.  Relevance of the c-statistic when evaluating risk-adjustment models in surgery.

Authors:  Ryan P Merkow; Bruce L Hall; Mark E Cohen; Justin B Dimick; Edward Wang; Warren B Chow; Clifford Y Ko; Karl Y Bilimoria
Journal:  J Am Coll Surg       Date:  2012-03-21       Impact factor: 6.113

3.  Portal vein thrombi after restorative proctocolectomy.

Authors:  Feza H Remzi; Victor W Fazio; Mustafa Oncel; Mark E Baker; James M Church; Boon S Ooi; Jason T Connor; Miriam Preen; David Einstein
Journal:  Surgery       Date:  2002-10       Impact factor: 3.982

4.  Extended Venous Thromboembolism Prophylaxis After Elective Surgery for IBD Patients: Nomogram-Based Risk Assessment and Prediction from Nationwide Cohort.

Authors:  Cigdem Benlice; Stefan D Holubar; Emre Gorgun; Luca Stocchi; Jeremy M Lipman; Matthew F Kalady; Bradley J Champagne; Scott R Steele
Journal:  Dis Colon Rectum       Date:  2018-10       Impact factor: 4.585

5.  The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study.

Authors:  C N Bernstein; J F Blanchard; D S Houston; A Wajda
Journal:  Thromb Haemost       Date:  2001-03       Impact factor: 5.249

6.  Who Should Get Extended Thromboprophylaxis After Bariatric Surgery?: A Risk Assessment Tool to Guide Indications for Post-discharge Pharmacoprophylaxis.

Authors:  Ali Aminian; Amin Andalib; Zhamak Khorgami; Derrick Cetin; Bartolome Burguera; John Bartholomew; Stacy A Brethauer; Philip R Schauer
Journal:  Ann Surg       Date:  2017-01       Impact factor: 12.969

7.  Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons.

Authors:  Karl Y Bilimoria; Yaoming Liu; Jennifer L Paruch; Lynn Zhou; Thomas E Kmiecik; Clifford Y Ko; Mark E Cohen
Journal:  J Am Coll Surg       Date:  2013-09-18       Impact factor: 6.113

8.  The American Society of Colon and Rectal Surgeons Clinical Practice Guideline for the Prevention of Venous Thromboembolic Disease in Colorectal Surgery.

Authors:  Fergal Fleming; Wolfgang Gaertner; Charles A Ternent; Emily Finlayson; Daniel Herzig; Ian M Paquette; Daniel L Feingold; Scott R Steele
Journal:  Dis Colon Rectum       Date:  2018-01       Impact factor: 4.585

9.  Defining high risk: cost-effectiveness of extended-duration thromboprophylaxis following major oncologic abdominal surgery.

Authors:  James C Iannuzzi; Aaron S Rickles; Kristin N Kelly; Fergal J Fleming; James G Dolan; John R T Monson; Katia Noyes
Journal:  J Gastrointest Surg       Date:  2013-10-08       Impact factor: 3.452

10.  Venous thromboembolism prophylaxis in inflammatory bowel disease flare-ups.

Authors:  Osama Kaddourah; Laith Numan; Sravan Jeepalyam; Omar Abughanimeh; Mouhanna Abu Ghanimeh; Khalil Abuamr
Journal:  Ann Gastroenterol       Date:  2019-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.